Status: G100 is being studied in a fully -
enrolled randomized Phase 2 trial in patients with follicular non-Hodgkin Lymphoma (FL) in combination with local radiation and Merck's anti-PD-1 agent, pembrolizumab, pursuant to a clinical collaboration with Merck.
The
phase 2
randomized clinical trial was conducted by the Eastern Cooperative Oncology Group,
enrolling 245 patients with stage 3 or stage 4 metastatic melanoma who had been treated with other drugs.